• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Abnormally short activated partial thromboplastin times are related to elevated plasma levels of TAT, F1+2, D-dimer and FVIII:C.

作者信息

Ten Boekel Edwin, Bartels Piet

机构信息

Laboratory for Clinical Chemistry, Hematology and Immunology, Medical Center of Alkmaar, Alkmaar, The Netherlands.

出版信息

Pathophysiol Haemost Thromb. 2002 May-Jun;32(3):137-42. doi: 10.1159/000065217.

DOI:10.1159/000065217
PMID:12372929
Abstract

Abnormally short activated partial thromboplastin times (APTTs) are associated with an increased risk of thrombotic disorders. We have examined the status of coagulation activity in subjects with short APTTs. In addition, the presence of the thrombotic risk factors G1691A-factor V, G20210A-prothrombin gene mutation and factor VIII coagulant activity (FVIII:C) was determined. Plasma levels of TAT, F1+2, D-dimer and FVIII:C were markedly higher in subjects with short APTTs compared with subjects with normal APTTs. APTTs were inversely related to TAT, F1+2, D-dimer and FVIII:C levels. The prevalence of G1691A-factor V and G20210A-prothrombin gene mutation between the group with short APTTs and the control group was not significantly different. Hence, these gene polymorphisms do not contribute to the increased risk of thrombosis associated with short APTTs. In conclusion, short APTTs are indicative of marked coagulation activity and elevated FVIII:C levels. Elevated FVIII:C levels may play a pathogenic role in the increased risk of thrombosis associated with abnormally short APTTs.

摘要

相似文献

1
Abnormally short activated partial thromboplastin times are related to elevated plasma levels of TAT, F1+2, D-dimer and FVIII:C.
Pathophysiol Haemost Thromb. 2002 May-Jun;32(3):137-42. doi: 10.1159/000065217.
2
Detection of shortened activated partial thromboplastin times: an evaluation of different commercial reagents.活化部分凝血活酶时间缩短的检测:不同商业试剂的评估
Thromb Res. 2007;121(3):361-7. doi: 10.1016/j.thromres.2007.05.006. Epub 2007 Jun 12.
3
Markers of activated coagulation in patients with factor V Leiden and/or G20210A prothrombin gene mutation.携带因子V莱顿突变和/或凝血酶原基因G20210A突变患者的活化凝血标志物。
Thromb Res. 2002 Jul 15;107(1-2):7-11. doi: 10.1016/s0049-3848(02)00189-5.
4
The use of coagulation activation markers (soluble fibrin polymer, TpP, prothrombin fragment 1.2, thrombin-antithrombin, and D-dimer) in the assessment of hypercoagulability in patients with inherited and acquired prothrombotic disorders.凝血激活标志物(可溶性纤维蛋白聚合物、凝血酶原片段1.2、凝血酶 - 抗凝血酶复合物和D - 二聚体)在遗传性和获得性血栓前状态患者高凝状态评估中的应用。
Blood Coagul Fibrinolysis. 2002 Apr;13(3):199-205. doi: 10.1097/00001721-200204000-00005.
5
Clinical impact of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations among sickle cell disease patients of Central India.印度中部镰状细胞病患者中因子 V 莱顿、凝血酶原 G20210A 和 MTHFR C677T 突变的临床影响。
Eur J Haematol. 2013 Nov;91(5):462-6. doi: 10.1111/ejh.12190. Epub 2013 Sep 16.
6
Marked elevation of thrombin generation in patients with elevated FVIII:C and venous thromboembolism.FVIII:C水平升高且患有静脉血栓栓塞症的患者凝血酶生成显著升高。
Br J Haematol. 2001 Dec;115(3):687-91. doi: 10.1046/j.1365-2141.2001.03146.x.
7
A laboratory evaluation into the short activated partial thromboplastin time.对活化部分凝血活酶时间缩短的实验室评估。
Blood Coagul Fibrinolysis. 2010 Mar;21(2):152-7. doi: 10.1097/MBC.0b013e3283365770.
8
Activated-protein-C resistance in cancer patients.癌症患者的活化蛋白C抵抗
Haemostasis. 1997 May-Jun;27(3):112-8. doi: 10.1159/000217442.
9
Evaluation of thrombotic children with malignancy.对患有恶性肿瘤的血栓形成儿童的评估。
Ann Hematol. 2005 Jun;84(6):395-9. doi: 10.1007/s00277-005-1004-x. Epub 2005 Feb 26.
10
Subjects with a shortened activated partial thromboplastin time show increased in-hospital mortality associated with elevated D-dimer, C-reactive protein and glucose levels.活化部分凝血活酶时间缩短的患者,其院内死亡率增加,且与D-二聚体、C反应蛋白及血糖水平升高相关。
Scand J Clin Lab Invest. 2003;63(6):441-8. doi: 10.1080/00365510310002338.

引用本文的文献

1
Lupus Anticoagulant Detection under the Magnifying Glass.放大镜下的狼疮抗凝物检测
J Clin Med. 2023 Oct 20;12(20):6654. doi: 10.3390/jcm12206654.
2
Laboratory Diagnosis of Antiphospholipid Syndrome: Insights and Hindrances.抗磷脂综合征的实验室诊断:见解与障碍
J Clin Med. 2022 Apr 13;11(8):2164. doi: 10.3390/jcm11082164.
3
[Practice of pharmaceutical thrombosis prophylaxis and anticoagulation in patients with sepsis and pre-existing anticoagulation or heparin-induced type II thrombocytopenia-Results of a nationwide survey in German intensive care units].
[脓毒症合并既往抗凝治疗或肝素诱导的II型血小板减少症患者的药物性血栓预防和抗凝治疗实践——德国重症监护病房全国性调查结果]
Anaesthesist. 2022 Mar;71(3):193-200. doi: 10.1007/s00101-021-01011-9. Epub 2021 Aug 5.
4
[Treatment of sepsis-induced coagulopathy : Results of a Germany-wide survey in intensive care units].[脓毒症诱导的凝血病的治疗:德国重症监护病房的一项全国性调查结果]
Anaesthesist. 2021 Aug;70(8):662-670. doi: 10.1007/s00101-021-00916-9. Epub 2021 Feb 8.
5
16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends.第十六届抗磷脂抗体国际大会抗磷脂综合征治疗趋势工作组报告。
Lupus. 2020 Oct;29(12):1571-1593. doi: 10.1177/0961203320950461.
6
System performance evaluation of the cobas t 711 and cobas t 511 coagulation analyzers in routine laboratory settings.在常规实验室环境中对 cobas t 711 和 cobas t 511 凝血分析仪的系统性能评估。
Blood Coagul Fibrinolysis. 2020 Oct;31(7):459-468. doi: 10.1097/MBC.0000000000000947.
7
VARIATION TENDENCY OF COAGULATION PARAMETERS IN DIFFERENT HYPOTHYROIDISM STAGES.不同甲状腺功能减退阶段凝血参数的变化趋势
Acta Endocrinol (Buchar). 2016 Oct-Dec;12(4):450-454. doi: 10.4183/aeb.2016.450.
8
Evaluation of Potential Clinical Surrogate Markers of a Trauma Induced Alteration of Clotting Factor Activities.创伤诱导凝血因子活性改变的潜在临床替代标志物评估
Biomed Res Int. 2016;2016:5614086. doi: 10.1155/2016/5614086. Epub 2016 Jun 28.
9
Global assays of hemostasis in the diagnostics of hypercoagulation and evaluation of thrombosis risk.全球止血检测在高凝诊断和血栓风险评估中的应用。
Thromb J. 2015 Jan 23;13(1):4. doi: 10.1186/s12959-015-0038-0. eCollection 2015.
10
Exercise induced hypercoagulability, increased von Willebrand factor and decreased thyroid hormone concentrations in sled dogs.运动引起的高凝状态、雪撬犬中血管性假性血友病因子增加和甲状腺激素浓度降低。
Acta Vet Scand. 2014 Feb 7;56(1):11. doi: 10.1186/1751-0147-56-11.